Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge is advising Immunovia in connection with its rights issue of up to SEK 202 million
Mandate

Vinge is advising Immunovia in connection with its rights issue of up to SEK 202 million

February 20, 2023 Capital Markets and Public M&A

Immunovia AB (publ) is a diagnostic company with the vision to revolutionize blood-based diagnostics and increase survival rates for patients with cancer. Immunovia’s shares are listed on Nasdaq Stockholm.

Vinge’s team primarily consisted of Dain Hård Nevonen, Amanda Knutsson, Anders Sundin Lundberg and Adrian Filipovic.

Related

Vinge advises ABG Sundal Collier in connection with Conapto's issue of subsequent senior secured bonds of SEK 500 million

 Vinge has advised ABG Sundal Collier as arranger in connection with Conapto Holding AB (publ)'s issue of subsequent senior secured bonds of SEK 500 million under the existing framework of SEK 2 billion.
April 24, 2026

Vinge advises GBL on its acquisition of BUKO Group

 Vinge, together with Latham & Watkins, advises Groupe Bruxelles Lambert (“GBL”) (Euronext Brussels: GBLB) on its acquisition of BUKO Group, a leading platform in temporary traffic management, from funds advised by Equistone Partners Europe and the founding family, while management will re-invest alongside GBL. The transaction, which is subject to customary approvals, will entail a EUR 0.5 billion equity investment by GBL.
April 24, 2026

Vinge advise Lagercrantz Group on the business acquisition of FMK Trafikprodukter

Lagercrantz Group, through its subsidiary Nordic Road Safety, has entered into an agreement to acquire the business and assets of FMK Trafikprodukter – a niche company specialising in CE-certified road barrier systems for the Swedish and Nordic infrastructure market.
April 24, 2026